Keyword Connections

pd-l1

Journals

10

1 PloS one

2 international immunopharmacology

3 Frontiers in immunology

4 Virology

5 Aging

6 the oncologist

7 oncoimmunology

8 aorta (stamford, conn)

9 journal of autoimmunity

10 immunity

Research Groups

0

No Research Group Connected

Bibliographies

41

1 The Transcription Factor Bhlhe40 Programs Mitochondrial Regulation of Resident CD8 T Cell Fitness and Functionality.

2 Pre-diagnostic anthropometry, sex, and risk of colorectal cancer according to tumor immune cell composition.

3 Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity.

4 Combinatorial treatment increases IKAP levels in human cells generated from Familial Dysautonomia patients.

5 MicroRNA-200a induces immunosuppression by promoting PTEN-mediated PD-L1 upregulation in osteosarcoma.

6 NFE2L2/KEAP1 mutations correlate with higher TMB value/PD-L1 expression and potentiate improved clinical outcome with immunotherapy.

7 Primary Sarcoma of Descending Aorta.

8 pd-1/pd-l1 blockade: have we found the key to unleash the antitumor immune response?

9 cancer immunotherapies targeting the pd-1 signaling pathway

10 reversing egfr mediated immunoescape by targeted monoclonal antibody therapy

11 prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma

12 advances of pd-1/pd-l1 inhibitors in tumor immunotherapy

13 regulation of pd-l1: emerging routes for targeting tumor immune evasion

14 Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors

15 EBV+ and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8+ Intratumoral Lymphocytes

16 PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression

17 Targeting Immune Cell Checkpoints during Sepsis

18 Prognostic value of PD-1, PD-L1 and PD-L2 deserves attention in head and neck cancer.

19 Reprogramming of radiation-deteriorated TME by liposomal nanomedicine to potentiate radio-immunotherapy.

20 Avelumab induces greater Fc-Fc receptor-dependent natural killer cell activation and dendritic cell crosstalk compared to durvalumab.

21 Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.

22 "Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.

23 Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy

24 Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells.

25 PD-L1 expression in tumour microenvironment supports the rationale for immune checkpoint blockade in classic Kaposi's sarcoma

26 Design of PD-L1 inhibitors for lung cancer.

27 Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

28 Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA.

29 Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.

30 Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.

31 Inhibition of the PD-1/PD-L1 signaling pathway enhances innate immune response of alveolar macrophages to mycobacterium tuberculosis in mice

32 Inhibitory Effect of Anoectochilus formosanus Extract on Hyperglycemia-Related PD-L1 Expression and Cancer Proliferation

33 durvalumab: an investigational anti-pd-l1 monoclonal antibody for the treatment of urothelial carcinoma

34 anti pd-l1 durvalumab combined with cetuximab and radiotherapy in locally advanced squamous cell carcinoma of the head and neck: a phase i/ii study (ducro)

35 association of pd-l1 and hif-1α coexpression with poor prognosis in hepatocellular carcinoma

36 clec1b expression and pd-l1 expression predict clinical outcome in hepatocellular carcinoma with tumor hemorrhage

37 enhancement of psma-directed car adoptive immunotherapy by pd-1/pd-l1 blockade

38 PD-L1 Nanobody Competitively Inhibits the Formation of the PD-1/PD-L1 Complex: Comparative Molecular Dynamics Simulations

39 Phospho-β-catenin expression in primary and metastatic melanomas and in tumor-free visceral tissues, and associations with expression of PD-L1 and PD-L2

40 Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination

41 Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination